Tumor Board Tuesday 2023: Breast Cancers


Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.


Supported by educational grants from Astellas; Astrazeneca Pharmaceuticals; Exelixis; Gilead Sciences, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp; and Seagen.


Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Johnathan Ebben, MD, PhD
Oncology Fellow
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
Madison, Wisconsin


#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time. You can join the conversation at https://twitter.com/TumorBoardTues

Tuesday, October 3, 2023Next TX: Heavily Pretreated HR+/HER2- mBC
AMA credit
Jane L. Meisel, MD
Associate Professor
Department of Hematology/Medical Oncology
Winship Cancer Institue of Emory University
Atlanta, Georgia

Dionisia Quiroga, DO, PhD
Assistant Professor
Division of Medical Oncology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Jane L. Meisel, MD
Consultant: AstraZeneca, Clovis, GE, Genentech, GSK, Novartis, Pfizer, Puma, Seagen, Olena
Research: AstraZeneca, Pfizer, Olena, Seagen

Dionisia Quiroga, DO, PhD has no real or apparent conflicts to disclose.
Tuesday, September 12, 2023HER2-Low mBC
AMA credit
Paolo Tarantino, MD
Research Fellow
Breast Oncology Center
Dana-Farber Cancer Institute

Megan Tesch, MD
Division of Breast Oncology
Dana-Farber Cancer Institute
Paolo Tarantino, MD
Consultant: AstraZeneca, Daiichi Sankyo, Gilead, Lilly

Megan Tesch, MD has no real or apparent conflicts to disclose.
Tuesday, August 1, 2023Early Stage High Risk TNBC Tx for Pts on Immunosuppression
AMA credit
Maryam Lustberg, MD, MPH
Associate Professor of Medicine, Medical Oncology Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center
Chief of Breast Medical Oncology at Yale Cancer Center

Adriana Kahn, MD
Assistant Professor of Medicine, Medical Oncology Breast Oncology and Drug Development
Yale School of Medicine
Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Lilly, Pfizer, Novartis

Adriana Kahn, MD has no real or apparent conflicts to disclose
Tuesday, July 11, 2023TROP2 TX in Localized TNBC
AMA credit
Aditya Bardia, MD, MPH
Director, Breast Cancer Research
Associate Professor, Harvard Medical School Attending Physician, Massachusetts General Hospital Boston, Massachusetts

Arielle J Medford, MD
Instructor, Harvard Medical School
Attending Physician, Massachusetts General Hospital Boston, Massachusetts
Aditya Bardia, MD, MPH
Consultant: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Phillips, Eli Lilly, Foundation Medicine
Research Grant: Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly

Arielle J Medford, MD
Advisor/Consultant: Guardant Health, Illumina, Natera
Tuesday, June 27, 2023TX Beyond Progression on a CDK4/6i
AMA credit
Ilana Schlam, MD
Assistant Professor of Medicine - Tufts University
Breast Medical Oncologist - Division of Hematology & Oncology Tufts Medical Center

Sarah Sammons, MD
Associate Director Metastatic Breast Cancer Program Department of Breast Oncology Program
Dana Farber Cancer Institute, Harvard Medical School
Ilana Schlam, MD has no real or apparent conflicts to disclose

Sarah Sammons, MD
Consultant: AstraZeneca, Daichi Sankyo, Eli Lilly, Incyclix, Novartis, Pfizer, Seagen, Sermonix
Research: AstraZeneca, Eli Lilly, Incyclix, Seagen, Sermonix
Tuesday, May 16, 2023Utilizing Baby Tam
AMA credit
Eleonora Teplinsky, MD
Head, Breast Medical Oncology Valley Health System
Clinical Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai

Prarthna Bhardwaj, MD, FACP
University of Massachusetts Chan Medical School
Baystate, Springfield, MA
Eleonora Teplinsky, MD
Medical Advisor: FloHealth, Sermo
Advisory Board: AstraZeneca

Prarthna Bhardwaj, MD, FACP
Stock: Doximity
Honoraria: Doximity
Tuesday, April 18, 2023Treating the Younger BRCA+ BC Patient
AMA credit
Jennifer K. Litton, MD
Vice President & Professor
Clinical Research and Dept. of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Marija Sullivan, MD
Hematology/Oncology Fellow
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas
Jennifer K. Litton, MD
The University of Texas MD Anderson Cancer Center: Certis

Marija Sullivan, MD has no real or apparent conflicts to disclose

Stay tuned for upcoming conversations!


Oncologists and other clinicians who treat patients with breast cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of all types of breast cancers. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in breast cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.


This activity is designed to meet the needs of medical, surgical and radiation oncologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with breast cancer.


Upon completion of this educational activity, participants will be able to:


There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

If you wish to claim credit for your participation in TBT conversations from March 21, 2023 – Present you can do so here: www.integrityce.com/TBTeval23




Physician Continuing Education

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this live material for a maximum of 7.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

Johnathan Ebben, MD, PhD
Other (CEO): NanoRED

The Integrity Continuing Education, Inc. planners and managers and Tumor Board Tuesday patient planner do not have any financial relationships or relationships to products or devices with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.